The effect of an anti-VEGF drug on proliferative retinopathy.

The effect of an anti-VEGF drug on proliferative diabetic retinopathy complicated with diabetic macular edema.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs031180307

Enrollment

Registered

2019-03-15

Start date

2018-08-24

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic retinopathy

Interventions

Intravitreal aflibercept injection

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Diabetic retinopathy with macular edema and non-perfusion area

Exclusion criteria

Exclusion criteria: Posttreatment for diabetic retinopath

Design outcomes

Primary

Measure	Time frame
Change of non-perfusion area	—

Secondary

Measure	Time frame
Change of visual acuity, retinal thickness and neovascularization	—

Contacts

Public ContactShigehiko Kitano

Tokyo Women`s Medical University Hospital

ge2s-ktn@asahi-net.or.jp+81-3-3353-8111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026